Search results
Showing 16 to 25 of 25 results for avelumab
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
Discontinued [GID-TA10210]
atomoxetine and dexamfetamine (review) 25 September 2005 ID3735 Avelumab for maintenance treatment of locally advanced or metastatic...
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Hundreds of people with some forms of urothelial cancer to receive new treatment
People with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment – avelumab – following its recommendation for funding
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.